Weekly update Companies AI-cruiter Recruiting

DICE Therapeutics

Founded: 2013

Location: South SF, CA

Employee range: 50 - 200

Clinical stage: Clin1

Therapy area: Psoriasis, immune-mediated conditions

Drug types: IMM, DRM, GI, ONC

Lead product: DC-806

Product link: https://www.dicetherapeutics.com/pipeline/

Funding: $345M stock Oct 2022; $204M IPO Sep 2021; $60M C-1 Aug 2021; $80M C Jan 2021

dicetherapeutics.com

linkedin.com

job board

Short description:

Small molecule compounds that act by unlocking protein-protein interfaces

Drug notes:

DC-853 Clin0 psoriasis, immune-mediated conditions; 5 undisclosed programs RD psoriasis, immune-mediated conditions, IBD, fibrosis, immuno-oncology, undisclosed

Long description:

DICE Therapeutics is discovering novel small molecules that can be used to treat various inflammatory diseases. Many current medicines to treat inflammatory diseases are not suited for chronic treatment as they would require regular patient monitoring and administration through injections or intravenous infusions. DICE is using their DELSCAPE platform to identify oral small molecules that modulate the binding of an inflammatory cytokine to its receptor as effectively as systemic biologics. Their growing pipeline of oral therapeutic candidates includes their lead program, DC-806 , that targets the IL-17 cytokine for psoriasis and other IL-17 mediated diseases.

Jobs:

Main

Contact: recruit@workinbiotech.com